Rostrum® Large Breed

Tablets.

Broad-spectrum antimicrobial.

Each oral tablet contains:
Enrofloxacin …………………… 150 mg
Excipients c.s.p…………………. 1 tablet

Rostrum® Large Race is a broad-spectrum antibacterial, recommended for the treatment of:

• Gastrointestinal tract infections (Escherichia coli, Salmonella spp., Proteus spp.).
• Respiratory tract infections (Pasteurella spp., Bordetella spp., Klebsiella spp.).
• Genitourinary infections such as nephritis, pyelonephritis, cystitis (Escherichia coli, Corynebacterium pyogenes, Staphylococcus aureus and Streptococcus spp.).
• Skin infections.
• Ear canal infections and otitis (Escherichia coli, Staphylococcus aureus, and Streptococcus spp.).
• Dermatitis, infected wounds (Escherichia coli, Klebsiella spp., Staphylococcus aureus and Streptococcus spp.).

Oral.

• Dosage of the active ingredient: 150 mg of Enrofloxacin / 30 kg body weight per day for 7 to 10 days.
  Half the dose may be given, twice a day.
• Product dosage: 1 tablet / 30 kg body weight per day for 7 to 10 days.

Dogs.

• Enrofloxacin is contraindicated in animals with hypersensitivity to quinolones.
• Do not administer to small to medium breed dogs, less than 1 year old, or large breed dogs less than 1 1/2 years old.
• Do not administer to animals with cartilaginous growth disorders.
• The use of Enrofloxacin may cause the formation of crystals in urine, so it is recommended not to administer it in dehydrated animals.
• It is not recommended for use during pregnancy and/or breastfeeding.

• Arthropathies have been reported in immature animals, especially dogs. The risk of arthropathy increases when the dose is increased, however, it has also been reported when recommended doses are used in dogs.
• Other adverse effects that have been described in very rare cases (less than 1 animal in 10,000 animals, including isolated reports) include vomiting, anorexia, increased liver enzymes, ataxia, seizures, depression, lethargy, and nervousness.

• Fluoroquinolones, such as Enrofloxacin, should not be used as a first line of treatment, unless there is no therapeutic alternative available. When used as a second treatment, it should be on the basis of susceptibility studies.
• Keep out of reach of children and pets.

• Do not handle by people who are hypersensitive to quinolones.
• In case of contact with skin, eyes or mucous membranes, wash immediately with plenty of water.
• In case of accidental ingestion, go immediately to a medical center and show the product insert.

Compounds containing di- or trivalent cations such as Aluminum, Calcium, Magnesium, Iron or Zinc may decrease the absorption of Enrofloxacin. Thus, for example, antacids containing cations (Mg2+, Al3+, Ca2+) can bind to enrofloxacin and prevent its absorption.
Sucralfate may inhibit the absorption of enrofloxacin. It is recommended to separate both dosages for at least two hours.
Enrofloxacin given with Theophylline may increase your serum levels. In dogs, the clearance of theophylline was reduced by 43% when co-administered with enrofloxacin at doses of 5mg/kg every 24 hours.
Concomitant administration with other drugs that have hepatic metabolism may affect the pharmacokinetics of one or both drugs.

Store between 15 and 30°C, away from light.

Empty containers can be discarded as household waste, without any special precautions.
Do not dispose of containers with product residues on the ground or in waterways.
For expired or unused products, contact the manufacturing laboratory.

Sale under prescription Withheld Veterinary Doctor.
For export: Sale by prescription Veterinary Medical

VETERINARY USE

Chile: Reg. SAG N° 721
Costa Rica: Reg. No. MV-5699
El Salvador: VE2014034902
Peru: Reg. SENASA F.83.21.I.0063
Rep. Dominican:Reg. No. 12636

Box with 10 tablets

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.